Psoriatic Arthritis

Tofacitinib may offer an effective oral option for patients with psoriatic arthritis.

Inflectra biosimilar treats conditions such as Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis.

Study finds 15.5% of all psoriasis patients had undiagnosed psoriatic arthritis.

Tofacitinib is an oral Janus kinase inhibitor that improves the signs and symptoms of psoriatic arthritis.

The oral Janus kinase inhibitor tofacitinib treats adults with active psoriatic arthritis (PsA).

Biosimilar infliximab-dyyb (Inflectra) treats a variety of autoimmune diseases.

Biosimilar infliximab-dyyb (Inflectra) treats a variety of autoimmune diseases, including Crohn’s disease, rheumatoid arthritis, and psoriatic arthritis.

Ixekizumab (Taltz) approved for moderate-to-severe plaque psoriasis in adults.

Etanercept shows sustained efficacy treating the symptoms of 3 juvenile idiopathic arthritis categories.

Toll-like receptor 4 behave differently on psoriasis skin compared with uninvolved skin.

There are several ongoing global phase 3 clinical trials for biosimilar adalimumab, which treats conditions such as rheumatoid arthritis, psoriatic arthritis, and Crohn's Disease.

Psoriatic arthritis patients who achieve persistent minimal disease activity more likely to experience long-term improvement with golimumab.

Psoriatic arthritis patients are more likely to develop conditions such as hypertension, diabetes, obesity, and dyslipidemia.

Sernivo Spray treats mild-to-moderate plaque psoriasis in patients 18 years of age and up.

Higher risk of serious infection found with adalimumab and infliximab compared with nonmethotrexate and nonbiologic therapies.

Brodalumab is monoclonal antibody that targets the IL-17 receptor.

Cutaneous psoriasis used to describe an individual who suffered from the disease for at least a decade.

Patients with inflammatory rheumatic diseases may not need more frequent vaccinations.

Cosentyx was previously approved for the treatment of moderate-to-severe plaque psoriasis.

Cosentyx was previously approved for the treatment of moderate-to-severe plaque psoriasis.

Researchers compare efficacy and side effects of different psoriatic arthritis treatment options.

Researchers compare efficacy and side effects of different psoriatic arthritis treatment options.

Research compares multidimensional approaches with uni-dimensional interventions.

Researchers evaluate association between psoriasis and cancer.

Prescription drugs costs for patients with psoriatic arthritis tended to be higher than comparable costs for ankylosing spondylitis.